Portable microfluidic chip for detection of Escherichia coli in produce and blood

Wang, Shuqi; İnci, Fatih; Chaunzwa, Tafadzwa L.; Ramanujam, Ajay; Vasudevan, Aishwarya; Subramanian, Sathya; Ip, Alexander Chi Fai; Sridharan, BanuPriya; Gürkan, Umut A.; Demirci, Utkan

doi:10.2147/ijn.s29629

Cited by 40 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To capture E. coli on microfluidic chips, we utilized a Protein G-based surface chemistry that allows to immobilize antibodies in a favorable orientation 18 . It was previously shown that anti-LPS presented highest capture efficiency among a set of antibodies (antiflagellin, anti-LPS and CD14) for on-chip E. coli capture when Protein G based surface chemistry was performed 6 . We adapted the surface chemistry for gold-coated substrates, to target E. coli capture on a microfluidic chip.…”

Section: Resultsmentioning

confidence: 99%

“…Developing such platforms that are affordable and rapid for infectious diseases is one of the top priorities for improving human health at the point-of-care (POC) settings 1 2 3 4 . Currently, the standard testing for pathogen detection and quantification are based on cell culture methods, which take 48 to 72 hours 5 6 7 . Other detection methods such as polymerase chain reaction (PCR) and enzyme linked immunosorbent assay (ELISA), have been widely used to detect and quantify pathogens with high sensitivity and specificity 8 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Portable Microfluidic Integrated Plasmonic Platform for Pathogen Detection

Tokel

Yıldız

İnci

et al. 2015

Sci Rep

Self Cite

180

123

View full text Add to dashboard Cite

Timely detection of infectious agents is critical in early diagnosis and treatment of infectious diseases. Conventional pathogen detection methods, such as enzyme linked immunosorbent assay (ELISA), culturing or polymerase chain reaction (PCR) require long assay times, and complex and expensive instruments, which are not adaptable to point-of-care (POC) needs at resource-constrained as well as primary care settings. Therefore, there is an unmet need to develop simple, rapid, and accurate methods for detection of pathogens at the POC. Here, we present a portable, multiplex, inexpensive microfluidic-integrated surface plasmon resonance (SPR) platform that detects and quantifies bacteria, i.e., Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) rapidly. The platform presented reliable capture and detection of E. coli at concentrations ranging from ~105 to 3.2 × 107 CFUs/mL in phosphate buffered saline (PBS) and peritoneal dialysis (PD) fluid. The multiplexing and specificity capability of the platform was also tested with S. aureus samples. The presented platform technology could potentially be applicable to capture and detect other pathogens at the POC and primary care settings.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Portable Microfluidic Integrated Plasmonic Platform for Pathogen Detection

Tokel

Yıldız

İnci

et al. 2015

Sci Rep

Self Cite

180

123

View full text Add to dashboard Cite

show abstract

“…Bacterial cells were quantified with green fluorescence, when exposed to blue light. In addition, Wang et al 61 developed a portable PMMA/glass hybrid microfluidic immunochip for detecting E. coli in produce and milk. The PMMA and glass plates were assembled with double-sided adhesive tape and the microchannels were functionalized using Protein G and NeutrAvidin based methods.…”

Section: Biomarker Detection Methods For Disease Diagnosis Using Mmentioning

confidence: 99%

“…These microfluidic platforms includes glass, 21, 46, 47 polydimethylsiloxane (PDMS), 45, 48, 49 poly(methyl methacrylate) (PMMA), 36, 50, 51 poly(cyclic olefin), 52, 53 paper-based, 23, 54–59 and hybrid devices. 36, 60, 61 …”

Section: Introductionmentioning

confidence: 99%

Biomarker detection for disease diagnosis using cost-effective microfluidic platforms

Sanjay

Dou

et al. 2015

Analyst

236

171

View full text Add to dashboard Cite

Early and timely detection of disease biomarkers can prevent the spread of infectious diseases, and drastically decrease the death rate of people suffering from different diseases such as cancer and infectious diseases. Because conventional diagnostic methods have limited application in low-resource settings due to the use of bulky and expensive instrumentation, simple and low-cost point-of-care diagnostic devices for timely and early biomarker diagnosis, is the need of the hour, especially in rural areas and developing nations. The microfluidics technology possesses remarkable features for simple, low-cost, and rapid disease diagnosis. There have been significant advances in the development of microfluidic platforms for diseases biomarker detection. This article reviews recent advances in biomarker detection using cost-effective microfluidic devices for disease diagnosis, with the emphasis on infectious disease and cancer diagnosis in low-resource settings. This review first introduces different microfluidic platforms (e.g. polymer and paper-based microfluidics) used for disease diagnosis, with a brief description of their common fabrication techniques. Then, it highlights various detection strategies for disease biomarker detection using microfluidic platforms, including colorimetric, fluorescence, chemiluminescence, electrochemiluminescence (ECL), and electrochemical detection. Finally, it discusses the current limitations of microfluidics devices for disease biomarker detection and the future perspectives.

show abstract

“…Advances in nanotechnology and microfluidic platforms rapidly enable significant developments of biosensing technologies and medical diagnostics (Wang et al, 2012a; Wang et al, 2012b). Particularly, advances in micro-nanofabrication technologies allow for developing rapid, user-friendly, accurate and specific diagnostic tools/methods, which achieve low detection limits of the target analytes/cells.…”

Section: Recent Advances In Nanotechnological Tools For Diagnosis mentioning

confidence: 99%

Recent advances in micro/nanotechnologies for global control of hepatitis B infection

Yıldız

İnci

Wang

et al. 2015

Biotechnology Advances

Self Cite

View full text Add to dashboard Cite

The control of Hepatits B virus (HBV) infection is a challenging task, specifically in developing countries where there is limited access to diagnostics and antiviral treatment mainly due to high costs and insufficient healthcare infrastructure. Although current diagnostic technologies can reliably detect HBV, they are relatively laborious, impractical and expensive for resource-limited settings. Advances in micro/nanotechnology are pioneering the development of new generation methodologies in diagnosis and screening of HBV. Owing to combination of nanomaterials (metal/inorganic nanopaticles, carbon nanotubes, etc.) with microfabrication technologies, utilization of miniaturized sensors detecting HBV and other viruses from ultra-low volume of blood, serum and plasma is realized. The state-of-the-art microfluidic devices with integrated nanotechnologies potentially allow for HBV screening at low cost. This review aims to highlight recent advances in nanotechnology and microfabrication processes that are employed for developing point-of-care (POC) HBV assays.

show abstract

Portable microfluidic chip for detection of Escherichia coli in produce and blood

Cited by 40 publications

References 39 publications

Portable Microfluidic Integrated Plasmonic Platform for Pathogen Detection

Portable Microfluidic Integrated Plasmonic Platform for Pathogen Detection

Biomarker detection for disease diagnosis using cost-effective microfluidic platforms

Recent advances in micro/nanotechnologies for global control of hepatitis B infection

Contact Info

Product

Resources

About